John, you didn't call the timing at all. I can plainly see you made two separate threads where you said the data would be released on Sunday, and where you said it wouldn't be.
Otherwise, we simply can go round and round on this, but the press release was just not enough... hours to go.
(I mis-spoke... hopefully this will get past the spam bots....)
That is not correct. Those missing 9 are those who got both the tPA and mechanical reperfusion. Those 9 increased the placebo Excellent results to 6.6%. Not results I would expect out of dead people.
If this theory about Sabby is correct, it means it will remove an impediment to upside. But it also means that many new shares will be in the new tradable float. So: I don't know!
Well. Total patient on placebo count was 61. 6.6% of placebo patients had an "Excellent" outcome.
The comparison excluded 9 placebo patients -- those who received both tPA and mechanical reperfusion, to avoid "confounding"' the less-than-36-hour MultiStem/placebo comparison. Presumably some less-than-36-hour MultiStem patients were excluded as well, but we can't know how many.
In the less-than-36-hour comparison, there were 52 placebo patients. Excellent outcome was at 1.9%. To get an Excellent outcome of 6.6% you need to have 3 out of the 9 remaining patients have an Excellent outcome:
6.6% out of 61 is 4.
1.9% out of 52 is 1.
By the way, this means that (just) tPA and mechanical reperfusion, plus placebo, gave an Excellent outcome 33.3% of the time.
A reverse conversion is a trade an investor makes, not a company, and it is not illegal... please educate me if I am wrong.
Thanks, I confused the 1-star and 2-star notes at first.
Here is one more for you to consider:
From all patients, more MultiStem patients received an excellent outcome than placebo, by a ratio of 2.33. If the primary or secondary endpoints did not on average show a significant change between MultiStem and placebo, doesn't this mean that many MultiStem patients did worse than placebo, or that (in the best scenario) the least bad cases of stroke were not improved (at all) by Multistem? (I posited this scenario before the trial results were available!)
It's from the 2015 final program book. Perhaps they had the contents of last year there as well, or made a mistake.
Hello again, lobsterpot1989.
Maybe, maybe.... APD371 data would probably be the only reason though.
I would like to hope that the conditions support Multistem as a treatment. How I see it going down is that the conference presentation won't have enough new information to prevent a further drop next week, but then they will release further data down the road which will raise the stock price back up.
NBS slashed death rates to 0 in its November trial results. NBS now has the same perceived problem ATHX might develop: not enough $$$ to properly commercialize. NBS will need a private investor or public secondary imminently, maybe why the stock price is doing not so great.
I don't think those numbers are right... it's 13.64m as of March 31. If it is correct that Sabby (big shareholder) had a friendly entity short some shares to cash out warrants, the share interest should have really decreased as of a few days ago. (won't see for a few weeks)
Methods: Full thickness thermal burns were created on the backs of anesthetized Gottingen mini-swine using a custommade device containing a brass block heated to 200°C and applied at a pressure of 0.4kg/cm2 for 1 minute. Two days postinjury the wounds underwent fascial excision and each animal was randomized to receive either Integra seeded with autologous ADRCs or control vehicle. All wounds were followed using digital imaging. Full-thickness biopsies were obtained at 7, 14 and 21 days after injury to evaluate dermal regeneration, vascularization and remodeling. Histology as well as clinical wound healing were graded and assessed by experienced study blinded reviewers.
Results: In vitro analysis demonstrated that freshly isolated ADRCs adhered and propagated on the dermal matrix. Histologic evaluation of wounds receiving ADRCs delivered with Integra demonstrated increased blood vessel density, lumen size and accelerated maturation in both the wound bed tissue beneath the Integra as well as within the Integra matrix proper. Integra wound matrix reduced wound contraction. There was no significant difference in wound contraction between wounds receiving Integra with ADRCs or its control vehicle, at day 21.
Conclusions: Our data suggest that seeding ADRCs onto this dermal substitute enhances tissue integration by increasing wound vascularization and matrix remodeling. These results provide new insights for novel strategies for skin regeneration after thermal burn injury, consisting of the combination of ADRCs with engineered biomaterials. Applicability of Research to Practice: Further development of matrix scaffold engineered with ADRCs may lead to improved healing in future clinical trials.
External Funding: BARDA Contract No. HHSO100201200008C.
Page 199 out of 297 pages. Doubt any HFTs will notice. The study result is there already. As always, the headline is a bit iffy in the final measurements. ("no significant difference in wound contraction" at day 21), Let me post the abstract here.
Autologous Adipose-Derived Regenerative Cells (ADRCs) Seeded in Collagen Scaffold Improves Dermal Regeneration, Enhancing Early Vascularization and Structural Organization Following Thermal Burn Injury P. Foubert, PhD, S. Barillas, BSc, I. Hakim, PhD, A. Gonzalez, BS, C. Meschter, DVM, PhD, M. Tenenhaus, MD, FACS, J. Fraser, PhD Cytori Therapeutics, San Diego, CA; Comparative Biosciences, Inc, Sunnyvale, CA; University of California, San Diego - Department of Surgery, San Diego, CA
Introduction: Adipose Derived Regenerative Cells (ADRCs) are currently being studied in an effort to optimize tissue repair and wound healing. The regenerative potential and proangiogenic activity of these cells have the potential to address critical deficiencies complicating burn and wound healing. Integra Dermal Regeneration Template (IDRT) wound matrix has been shown to facilitate fibroblast in-growth and formation of wound bed tissue following thermal burn injury. The success of tissue regeneration depends on optimal vascularization, wound bed preparation and bio-integration of the construct. The purpose of this study was to evaluate whether seeding ADRCs onto Integra would affect matrix properties and enhance wound healing.
(continued on next post)